Company Description

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States.

The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors.

It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.

Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Qualigen Therapeutics, Inc.

Country	United States
Founded	1996
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Michael S. Poirier

Contact Details

Address: 2042 Corte Del Nogal, Carlsbad California, California 92011 United States
Phone	(760) 918-9165
Website	qualigeninc.com

Stock Details

Ticker Symbol	QLGN
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001460702
CUSIP Number	74754R103
ISIN Number	US74754R2022
Employer ID	26-3474527
SIC Code	2834

Key Executives

Name	Position
Michael S. Poirier	President, Chief Operating Officer, Chief Executive Officer and Chairman
Christopher L. Lotz	Vice President of Finance, Chief Financial Officer and Corporate Secretary

Latest SEC Filings

Date	Type	Title
Jul 2, 2024	10-Q	Quarterly Report
May 30, 2024	8-K	Current Report
May 14, 2024	NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
May 6, 2024	S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
May 3, 2024	424B3	Prospectus
May 2, 2024	EFFECT	Notice of Effectiveness
May 1, 2024	POS AM	Post-Effective amendments for registration statement
Apr 16, 2024	8-K	Current Report
Apr 8, 2024	10-K	Annual Report
Apr 1, 2024	NT 10-K	Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

View All SEC Filings